Seeking Alpha
10 Oct 2026, 03:42 UTC · 1h ago
Glaukos: The Second J-Code Rewrites The Risk Math
Impact · against what's priced in
Glaukos shows strong momentum with raised 2026 guidance and high gross margins, though the market remains cautious regarding Medicare coverage risks for iDose TR. The diversification into a second J-coded product (Epioxa) serves as a hedge against potential LCD restrictions, reducing the binary risk profile of the stock.
- GKOS+0.40
No priced-in read yet
- In context
Raised 2026 sales guidance to $680–700M and a 50% YoY increase in Q2 net sales to $185.6M signal strong operating leverage, though Medicare contractor coverage limitations for iDose TR remain a key risk factor.
Read from the article alone
